TY - JOUR
T1 - Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors
AU - Busca, Alessandro
AU - Novarino, Anna
AU - de Fabritiis, Paolo
AU - Picardi, Alessandra
AU - Zeuli, Massimo
AU - Locatelli, Franco
AU - Bertetto, Oscar
AU - Falda, Michele
PY - 2006/6
Y1 - 2006/6
N2 - Background: The aim of the study was to evaluate the feasibility and efficacy of a non-myeloablative regimen to achieve complete donor chimerism after stem cell transplantation (SCT) in patients with metastatic solid tumors. Patients and methods: Seven patients with renal cell carcinoma (RCC), 3 with colorectal carcinoma and 1 with soft tissue sarcoma received an allogeneic SCT after fludarabine (90 mg/m 2) and TBI 200 cGy. Results: At day 30, median donor chimerism was 94%. Regression of tumor metastases has been observed in 1 patient with RCC. Overall, 8 patients (73%) died from progressive disease (median progression-free survival 3.7 months) and 1 (9%) from treatment-related complications; 2 patients were alive 152 and 862 days after transplantation. Conclusions: Our preliminary results suggest that non-myeloablative SCT for metastatic solid tumors is feasible, although may lead to durable responses in a minority of patients. Careful patient selection seems to be mandatory in this transplant setting.
AB - Background: The aim of the study was to evaluate the feasibility and efficacy of a non-myeloablative regimen to achieve complete donor chimerism after stem cell transplantation (SCT) in patients with metastatic solid tumors. Patients and methods: Seven patients with renal cell carcinoma (RCC), 3 with colorectal carcinoma and 1 with soft tissue sarcoma received an allogeneic SCT after fludarabine (90 mg/m 2) and TBI 200 cGy. Results: At day 30, median donor chimerism was 94%. Regression of tumor metastases has been observed in 1 patient with RCC. Overall, 8 patients (73%) died from progressive disease (median progression-free survival 3.7 months) and 1 (9%) from treatment-related complications; 2 patients were alive 152 and 862 days after transplantation. Conclusions: Our preliminary results suggest that non-myeloablative SCT for metastatic solid tumors is feasible, although may lead to durable responses in a minority of patients. Careful patient selection seems to be mandatory in this transplant setting.
KW - Allogeneic stem cell transplantation
KW - Graft versus tumor effect
KW - Nonmyeloablative regimen
KW - Solid tumors
UR - http://www.scopus.com/inward/record.url?scp=33748494907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748494907&partnerID=8YFLogxK
U2 - 10.1080/10245330600775253
DO - 10.1080/10245330600775253
M3 - Article
C2 - 17325957
AN - SCOPUS:33748494907
VL - 11
SP - 171
EP - 177
JO - Hematology
JF - Hematology
SN - 1024-5332
IS - 3
ER -